Veracyte Q2 revenue rises 14%, beats expectations

Overview

• Veracyte Q2 revenue rises 14% yr/yr to $130.2 mln, beating expectations

• Adjusted EBITDA for Q2 improves 49% to $35.8 mln

• Co raises full-year 2025 testing revenue guidance

Outlook

• Veracyte raises 2025 testing revenue guidance to $477 mln to $483 mln

• Company expects 2025 testing revenue growth of 14% to 15% y/y

• Veracyte initiates 2025 total revenue guidance of $496 mln to $504 mln

• Company raises 2025 adjusted EBITDA guidance to 23.5% of revenue

Result Drivers

• DECIPHER GROWTH - Decipher achieved 28% volume growth, driving revenue increase

• AFIRMA VOLUME - Afirma volume met expectations, contributing to testing revenue growth

• FRENCH PROCEEDINGS - Resolution of French subsidiary proceedings enabled strategic investments, supporting growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Veracyte Inc is $43.00, about 41.8% above its August 5 closing price of $25.01

• The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 47 three months ago

Press Release: ID:nBwFP9Tsa